ReviewFrontiers in endocrinology2026

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.

Filip Kierzkowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.